Skip to main content

Rohto Pharmaceutical

Rohto Pharmaceutical Co Ltd is a Japanese healthcare and cosmetics manufacturer producing over-the-counter eye drops, skincare formulations, and non-prescription pharmaceuticals globally. The company manufactures eye care solutions under V Rohto and Rohto C3, alongside functional skincare products under brands including Hada Labo, Melano CC, and Dermacept. Principal revenues derive from direct product sales and wholesale distribution to retail pharmacies, drugstores, e-commerce channels, and supermarket chains across Japan, Asia, and international markets. Core end markets encompass retail consumers, eye care users, skincare shoppers, and drugstore customers globally. Rohto Pharmaceutical holds a market-leading global position in OTC eye care products and a dominant position in Asian hydrating skincare. The corporation is headquartered in Osaka, Japan, and its common stock trades on the Tokyo Stock Exchange.

5 of the funds FundTelligence covers report a position in Rohto Pharmaceutical.

Legal name
Rohto Pharmaceutical Co Ltd
Sector
Health Care
Country
Japan
Funds holding it
5

Funds holding Rohto Pharmaceutical

Loading...